A balanced portfolio

During our last financial year progress against our strategic objectives included:

• Conducted a strategic review of R&D to establish a more balanced and focused portfolio, aligned with company strategy

• Received positive determinations for our PRP in Colombia and Brazil, ensuring it will be treated in the same way as a conventionally bred animal
• Maintained effective engagement with the FDA regarding our PRP, gaining acceptance for animal characterisation submissions and proceeding to work on post-product approval compliance procedures
• Made initial submissions regarding the PRP to regulators in Canada and Japan
• Progressed projects focused on disease resistance, including beginning a new collaboration with The Roslin Institute

• Introduced a new-generation instrument and microfluidic chip for sexing semen, further increasing production efficiency
• Expanded the production of sexed semen containing a greater ratio of Y chromosomes, helping customers around the world produce more male offspring

• Continued collaborating with partners to explore how to accelerate genetic gain using embryonic stem cells

• Embedded our data analytics strategy across operations, enhancing our ability to identify and act on insights to accelerate genetic improvement
• Harnessed integrated data dashboards to drive continuous improvement of sexing technology and rapid resolution of any performance issues